PPA
CMTA

Parametric Portfolio Associates’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

Parametric Portfolio Associates’s Portfolio CMTA Stock Details CMTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-20,018
Closed -$338K – 3972
2017
Q3 		$338K Buy
+20,018
New +$327K ﹤0.01% 3625

Other funds holding CMTA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Parametric Portfolio Associates's CMTA Position: Q4 2017 in Review

Parametric Portfolio Associates sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q4 2017, closing a stake of 20,018 shares — an estimated $338K sold.

Parametric Portfolio Associates first reported a position in CMTA in Q3 2017 and held it in 1 quarter. The position peaked at $338K in Q3 2017. 37 funds tracked by Wall St. Rank hold CMTA as of Q4 2017.

  • Parametric Portfolio Associates reported no remaining Clementia Pharmaceuticals Inc. position as of Q4 2017 after selling out during the quarter.
  • Parametric Portfolio Associates sold 20,018 Clementia Pharmaceuticals Inc. shares in Q4 2017, an estimated $338K.
  • Parametric Portfolio Associates first reported a position in Clementia Pharmaceuticals Inc. in Q3 2017 and held it in 1 quarter.
  • Parametric Portfolio Associates's Clementia Pharmaceuticals Inc. position peaked at $338K in Q3 2017.
  • 37 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q4 2017.

Based on Parametric Portfolio Associates's 13F filing for Q4 2017, filed 14 Feb 2018.